Drug Trial Radar · NCT06168214
Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication
Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,404
Planned (sponsor's estimate)
Start
Sep 4, 2023
Primary completion
Nov 25, 2024
Study completion Dec 25, 2024
Sponsor
- Lead sponsor
- Xijing Hospital of Digestive DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are: * Main indicators: the eradication rate of Helicobacter pylori for eradication. * Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.
Conditions
- the Eradication Rates of Helicobacter Pylori
Interventions
Rabeprazloe+bismuth+amoxicillin+clarithromycinDrug
PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
Vonoprazan+amoxicillin+clarithromycin 14 daysDrug
VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
Vonoprazan+amoxicillin+clarithromycin 7 daysDrug
VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
Vonoprazan+tetracycline+furazolidone 14 daysDrug
VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
Vonoprazan+tetracycline+furazolidone 7 daysDrug
VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
Vonoprazan+amoxicillin+furazolidone 7 daysDrug
hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.
Vonoprazan+amoxicillin+tetracycline 14 daysDrug
hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.
Vonoprazan+amoxicillin 7 daysDrug
hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
Vonoprazan+amoxicillin 14 daysDrug
hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication rate of Helicobacter pyloriTime frame: Helicobacter pylori eradication rate assessed 4-8 weeks after completion of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ying han
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.